These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6491917)

  • 21. Is the use of a 200 ml vessel suitable for dissolution of low dose drug products?
    Crail DJ; Tunis A; Dansereau R
    Int J Pharm; 2004 Jan; 269(1):203-9. PubMed ID: 14698592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Apex Size on Dissolution Profiles in the USP II Paddle Apparatus.
    Yoshida H; Morita T; Abe Y; Inagaki A; Tomita N; Izutsu KI; Sato Y
    AAPS PharmSciTech; 2023 Dec; 25(1):9. PubMed ID: 38158516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding the impact of media viscosity on dissolution of a highly water soluble drug within a USP 2 mini vessel dissolution apparatus using an optical planar induced fluorescence (PLIF) method.
    Stamatopoulos K; Batchelor HK; Alberini F; Ramsay J; Simmons MJH
    Int J Pharm; 2015 Nov; 495(1):362-373. PubMed ID: 26363111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of two dissolution apparatuses with correlation of in vitro-in vivo data for prednisone and prednisolone tablets.
    Milsap RL; Ayres JW; Mackichan JJ; Wagner JG
    Biopharm Drug Dispos; 1979; 1(1):3-17. PubMed ID: 552859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered Media Flow and Tablet Position as Factors of How Air Bubbles Affect Dissolution of Disintegrating and Non-disintegrating Tablets Using a USP 4 Flow-Through Cell Apparatus.
    Yoshida H; Teruya K; Abe Y; Furuishi T; Fukuzawa K; Yonemochi E; Izutsu KI
    AAPS PharmSciTech; 2021 Aug; 22(7):227. PubMed ID: 34431011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies of variability in dissolution testing with USP apparatus 2.
    Gao Z; Moore TW; Smith AP; Doub WH; Westenberger BJ
    J Pharm Sci; 2007 Jul; 96(7):1794-801. PubMed ID: 17252609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissolution of USP prednisone calibrator tablets: effects of stirring conditions and particle size distribution.
    Röst M; Quist PO
    J Pharm Biomed Anal; 2003 Apr; 31(6):1129-43. PubMed ID: 12667929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions.
    Kukura J; Baxter JL; Muzzio FJ
    Int J Pharm; 2004 Jul; 279(1-2):9-17. PubMed ID: 15234789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of vibration and agitation speed on dissolution of USP prednisone tablets RS and various IR tablet formulations.
    Seeger N; Lange S; Klein S
    AAPS PharmSciTech; 2015 Aug; 16(4):759-66. PubMed ID: 26104919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel off-center paddle impeller (OPI) dissolution testing system for reproducible dissolution testing of solid dosage forms.
    Wang Y; Armenante PM
    J Pharm Sci; 2012 Feb; 101(2):746-60. PubMed ID: 22083630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stability of prednisone tablets submitted by U.S. hospitals.
    Juhl YH
    Am J Hosp Pharm; 1986 Jan; 43(1):98-102. PubMed ID: 3953589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of USP calibrator tablets in flow-through cell apparatus.
    Bielen N
    Int J Pharm; 2002 Feb; 233(1-2):123-9. PubMed ID: 11897416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New in vitro dissolution test apparatus.
    Nasir SS; Wilken LO; Nasir SM
    J Pharm Sci; 1979 Feb; 68(2):177-81. PubMed ID: 423087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Time and temperature dependence of disintegration and correlation between dissolution and disintegration rate constants.
    Carstensen JT; Kothari R; Prasad VK; Sheridan J
    J Pharm Sci; 1980 Mar; 69(3):290-4. PubMed ID: 7381704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peristaltic dissolution apparatus: prediction of relative in vivo performance of prednisone tablets in humans.
    Simmons DL; Legore AA; Picotte P
    J Pharm Sci; 1980 Feb; 69(2):220-2. PubMed ID: 7359333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The random vibration effects on dissolution testing with USP apparatus 2.
    Gao Z; Moore TW; Buhse LF; Doub WH
    J Pharm Sci; 2009 Jan; 98(1):297-306. PubMed ID: 18399543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple fiber-optic dual-beam UV/Vis system with application to dissolution testing.
    Johansson J; Cauchi M; Sundgren M
    J Pharm Biomed Anal; 2002 Jul; 29(3):469-76. PubMed ID: 12062647
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Velocity Field Visualization in USP Dissolution Apparatus 3 Using Particle Image Velocimetry.
    Perivilli S; Prevost R; Stippler E
    Pharm Res; 2017 Jun; 34(6):1330-1337. PubMed ID: 28409325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Three-stage sequential statistical dissolution testing rules.
    Tsong Y; Shen M; Shah VP
    J Biopharm Stat; 2004 Aug; 14(3):757-79. PubMed ID: 15468763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a Dissolution Method for Gliclazide Modified-Release Tablets Using USP Apparatus 3 with in Vitro-in Vivo Correlation.
    Bezerra KC; Pinto EC; Cabral LM; de Sousa VP
    Chem Pharm Bull (Tokyo); 2018; 66(7):701-707. PubMed ID: 29962453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.